The Growth-Hormone Axis: A Research Literature Overview

NOVA Q Research · Research Library

The Growth-Hormone Axis: A Research Literature Overview

What the published research examines across tesamorelin, IGF-1 LR3, ipamorelin, and CJC-1295 — four compounds acting at different nodes of the GH axis, with very different evidence maturity.

Neutral literature aggregation · Compiled by NOVA Q Research · Updated 2026-07-24 · 15 cited sources
In brief
  • Tesamorelin is the only compound here approved by the FDA for a specific indication, with several randomized controlled trials in one clinical population.
  • IGF-1 LR3 research is essentially all preclinical — rodent and ruminant infusion studies and in-vitro work.
  • Ipamorelin is characterized predominantly in rodent pharmacology (GH selectivity, bone endpoints, GI motility).
  • CJC-1295 has a small primary literature, limited to preclinical design work and small early-phase human pharmacology studies.

The growth-hormone (GH) axis links hypothalamic GHRH, ghrelin/GH-secretagogue-receptor signaling, pituitary GH, and hepatic IGF-1. The compounds here act at different nodes: tesamorelin and CJC-1295 are GHRH analogs, ipamorelin is a selective GH-secretagogue-receptor agonist, and IGF-1 LR3 is a modified IGF-1 analog acting downstream of GH. Their literatures range from multiple randomized clinical trials (tesamorelin) to small early-phase pharmacology or purely preclinical work.

Tesamorelin

Class / mechanism. A stabilized synthetic analog of human GHRH (a GHRH-receptor agonist).

Tesamorelin has the most clinically developed literature in this category, centered on randomized, placebo-controlled trials in people with HIV and excess visceral adipose tissue. Reported endpoints include visceral adipose tissue by CT, hepatic fat, circulating IGF-1, and lipid, glucose, and inflammatory markers. It is the only compound in this group FDA-approved for a specific indication (reduction of excess abdominal fat in HIV-associated lipodystrophy).

Selected literature

  1. Falutz J, et al. 2007. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med 357:2359–70. https://www.nejm.org/doi/full/10.1056/NEJMoa072375Randomized double-blind placebo-controlled trial on visceral fat and lipids.
  2. Falutz J, et al. 2010. “Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation.” J Acquir Immune Defic Syndr 53:311–22. PMID 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/Randomized trial with safety extension; body-composition outcomes.
  3. Stanley TL, et al. 2014. “Effect of tesamorelin on visceral fat and liver fat in HIV.” JAMA 312:380–9. https://jamanetwork.com/journals/jama/fullarticle/1890486Randomized clinical trial measuring hepatic fat by MR spectroscopy.
  4. Stanley TL, et al. 2011. “Effects of tesamorelin on inflammatory markers in HIV.” AIDS 25:1281–8. PMID 21516030. https://pubmed.ncbi.nlm.nih.gov/21516030/Analysis correlating inflammatory-marker change with visceral-fat reduction.
Where the evidence is limited. The randomized evidence is concentrated in a single clinical population (HIV-associated abdominal fat), so findings are not established as generalizable; long-term and non-HIV data are limited.

IGF-1 LR3

Class / mechanism. An N-terminally extended, Arg3-substituted analog of IGF-1 (“Long R3 IGF-I”) with reduced affinity for IGF-binding proteins; an IGF-1-receptor agonist acting downstream of GH.

The IGF-1 LR3 literature is essentially entirely preclinical: rodent and ruminant infusion studies and in-vitro/ex-vivo tissue and vascular models. Investigations characterize organ and gut growth, nitrogen/anabolic balance in catabolic models, and effects on circulating IGF-1/IGF-2 and binding proteins.

Selected literature

  1. Tomas FM, et al. 1992. “IGF-I and especially IGF-I variants are anabolic in dexamethasone-treated rats.” Biochem J 282:91–7. https://pubmed.ncbi.nlm.nih.gov/1540143/Compared native IGF-I with N-terminally modified variants on anabolic endpoints.
  2. Read LC, et al. 1992. “IGF-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats.” J Endocrinol 133:421–31. PMID 1613443. https://pubmed.ncbi.nlm.nih.gov/1613443/Gastrointestinal growth responses to IGF-I analogues in catabolic rats.
  3. Conlon MA, et al. 1995. “Long R3 IGF-I infusion stimulates organ growth but reduces plasma IGF-I/IGF-II in the guinea pig.” J Endocrinol 146:247–53. https://pubmed.ncbi.nlm.nih.gov/7561637/Infusion study measuring organ growth and circulating IGF concentrations.
  4. Gow IF, 2000. “Response of isolated ruminant mammary arteries to the Long R3 analogue of IGF-I.” Exp Physiol 85:275–9. PMID 10825414. https://pubmed.ncbi.nlm.nih.gov/10825414/Ex-vivo vascular-reactivity study of isolated arteries.
Where the evidence is limited. Available studies are preclinical and often use continuous infusion; there is no established randomized human clinical trial literature, and human pharmacokinetics, dosing, and safety are undefined.

Ipamorelin

Class / mechanism. A selective synthetic pentapeptide agonist of the GH-secretagogue receptor (a ghrelin-receptor agonist / GH secretagogue).

Ipamorelin is characterized predominantly in preclinical pharmacology. Founding work described its selectivity for GH release relative to other pituitary hormones; subsequent rodent studies examined bone mineral content and bone formation (including in glucocorticoid-treated models) and gastrointestinal motility in a postoperative-ileus model reflecting its ghrelin-mimetic activity.

Selected literature

  1. Raun K, et al. 1998. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol 139:552–61. https://pubmed.ncbi.nlm.nih.gov/9849822/Foundational pharmacology of GH-releasing potency and selectivity.
  2. Svensson J, et al. 2000. “The GH secretagogues ipamorelin and GHRP-6 increase bone mineral content in adult female rats.” J Endocrinol 165:569–77. https://pubmed.ncbi.nlm.nih.gov/10828840/Compared ipamorelin and GHRP-6 on bone-mineral-content endpoints.
  3. Andersen NB, et al. 2001. “Ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.” Growth Horm IGF Res 11:266–72. https://pubmed.ncbi.nlm.nih.gov/11735244/Bone-formation measures in glucocorticoid-treated rats.
  4. Venkova K, et al. 2009. “Efficacy of ipamorelin in a rodent model of postoperative ileus.” J Pharmacol Exp Ther 329:1110–6. https://pubmed.ncbi.nlm.nih.gov/19289570/Gastrointestinal transit in a rodent postoperative-ileus model.
Where the evidence is limited. The base is predominantly rodent preclinical pharmacology; robust randomized human efficacy and long-term safety data are not established, and it is not FDA-approved.

CJC-1295

Class / mechanism. A long-acting GHRH (GRF 1-29) analog; in its drug-affinity-complex (“DAC”) form it bioconjugates covalently to serum albumin to extend half-life (a GHRH-receptor agonist).

The CJC-1295 primary literature is small and concentrated in the mid-2000s: a rat study identifying the albumin-bioconjugate approach and its GRF-receptor activity, and early-phase human studies measuring GH and IGF-1 secretion, half-life, and GH pulsatility. Reported human data are limited to small healthy-adult cohorts.

Selected literature

  1. Jette L, et al. 2005. “hGRF(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295.” Endocrinology 146:3052–8. https://pubmed.ncbi.nlm.nih.gov/15817669/Preclinical characterization of the albumin-bioconjugate design.
  2. Teichman SL, et al. 2006. “Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults.” J Clin Endocrinol Metab 91:799–805. https://pubmed.ncbi.nlm.nih.gov/16352683/Early-phase human study of GH/IGF-1 responses and half-life.
  3. Ionescu M, Frohman LA. 2006. “Pulsatile GH secretion persists during continuous stimulation by CJC-1295.” J Clin Endocrinol Metab 91:4792–7. https://pubmed.ncbi.nlm.nih.gov/16957023/Human study of GH pulsatility under continuous GHRH-analog stimulation.
Where the evidence is limited. Human data are confined to small early-phase pharmacology studies in healthy volunteers; there are no large randomized controlled efficacy trials, limited long-term safety data, and no FDA approval.

How to read this report

This report aggregates published scientific literature for the compounds NOVA Q Research supplies in the Growth-Axis category. It describes what studies investigated, the models used, and the maturity of the evidence. It does not evaluate, recommend, or imply any use in humans or animals, and it is not medical, veterinary, or research-protocol advice. Where the record is preclinical or geographically concentrated, we say so. Every source is cited so it can be checked independently.

Browse the Growth-Axis catalog →
For research use only. Not for human or veterinary use. NOVA Q Research supplies research-grade materials for laboratory research use only. Nothing in this document is intended to diagnose, treat, cure, or prevent any disease, or to guide human or veterinary use. Statements have not been evaluated by the FDA. Citations are provided for reference and do not imply endorsement.